|
|
|
24.06.25 - 19:06
|
IDEXX Laboratories to Release 2025 Second Quarter Financial Results (Business Wire)
|
|
|
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day.
Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year.
The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-289-0462 or 1-323-794-2442 and reference passcode 595638.
2025 Investor Day
IDEXX Laboratories, Inc. will host its 2025 Investor Day on Thursday, August 14, 2025, at its corporate headquarters in Westbrook, Maine from 8:00 am to approximatel...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.05.25 - 12:36
|
IDEXX Laboratories Announces First Quarter Results (Business Wire)
|
|
|
Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic.
Organic revenue growth supported by benefits from IDEXX execution drivers, including continued solid new business gains and strong year-over-year global premium instrument installed base growth, including over 300 IDEXX inVue Dx™ placements.
Delivers EPS of $2.96, an increase of 5% as reported and 7% on a comparable basis, supported by gross margin expansion of 90 basis points as reported and 80 basis points on a comparable basis.
Adjusts 2025 revenue guidance to $4,095 million - $4,210 million, an increase of $40 million or ~1% at midpoint, reflecting benefits of foreign exchange impacts updated from prior estimates.
Updates guidance for 2025 reported revenue growth to 5% - 8% and reported CAG Diagnostics recurring revenue growth to 4% - 7%, while maintaining consistent outlook for 6% - 9% organic revenue growth and CAG Diagnostics recurring r...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
